NCT04463056已完成3 期
A Multicenter, Open Label, Randomized, Parallel-group Study of Efficacy and Safety of Eculizumab (JSC GENERIUM, Russia) vs. Soliris® (Alexion Pharma GmbH, Switzerland) in Patients With Paroxysmal Nocturnal Hemoglobinuria
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AO GENERIUM
- 入组人数
- 32
- 试验地点
- 8
- 主要终点
- Area under the LDH concentration-time curve (LDH AUC) during the maintenance therapy with the test drug or the reference drug
研究概览
简要总结
It is a multicenter, open-label, randomized, parallel-group study of the efficacy and safety of Elizaria® (eculizumab, GENERIUM JSC, Russia) versus Soliris® (Alexion Pharma GmbH, Switzerland) in patients with paroxysmal nocturnal hemoglobinuria.
详细描述
After screening, patients meeting all of the inclusion / non-inclusion criteria and vaccinated against meningococcal infections were divided into two subgroups according to the eculizumab treatment status (Soliris® naïve patients / patients who had received Soliris® at a maintenance dose prior to the trial inclusion). Each subgroup included an even number of patients to maintain recruitment balance. Then, patients of each subgroup were distributed into one of two treatment groups by the method of stratified block randomization at a 1:1 ratio into groups A and B, respectively. In the first group (Group A), patients received infusions of Elizaria (eculizumab, GENERIUM JSC), in the second one (Group B) - infusions of Soliris®.
The duration of participation of each patient in the study, including the screening period, was about 30 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent for participation in the study.
- •Men and women aged 18 to 65 years at the time of signing the Informed Consent Form.
- •Established diagnosis of paroxysmal nocturnal hemoglobinuria (PNH), confirmed by flow cytometry assessing the PNH red blood cell and white blood cell clone size, with intravascular hemolysis and current or previous concomitant clinical symptoms, irrespective of the need for blood transfusions and without signs of other disorders associated with bone marrow failure.
- •For patients, who have not received Soliris® before inclusion in this study: lactate dehydrogenase (LDH) level 1.5 times the upper limit of normal or higher as assessed by the central laboratory.
- •The patients receiving anticoagulants must take them at a stable dose for at least 4 weeks prior to screening. Patients receiving warfarin must have a stable international normalized ratio (INR) value. To confirm INR value stability, the patients have to provide a blood INR test at least 4 weeks prior to screening. The second INR assessment will be performed at the screening visit.
- •Documented vaccination against meningococcal infections (Neisseria meningitidis serogroups A, C, Y and W-135) the protective immunity of which did not wear off, at least 14 days prior to the administration of the first dose of the test or reference drug and the patient's consent for revaccination against meningococcal infections (Neisseria meningitidis serogroups A, C, Y and W-135) during participation in the current study if the protection from previous vaccination wears off.
- •Subjects' consent to use reliable contraceptive methods (the combination of at least 2 methods, including barrier contraception, for example, condoms with spermicide) from signing the Informed Consent Form for up to 10 weeks after stopping therapy.
排除标准
- •Hypersensitivity to the test drug, reference drug and their components.
- •Hypersensitivity to the active substance or any other component of the vaccine used to prevent meningococcal infection or a lifethreatening reaction to a previously administered vaccine containing similar ingredients.
- •Conditions associated with bone marrow failure and PNH clone (aplastic anemia, myelodysplastic syndrome, idiopathic myelofibrosis).
- •A history of infections caused by Neisseria meningitides.
- •Active systemic bacterial, viral, or fungal infection within 14 days prior to the administration of the first dose of the test or reference drug.
- •Fever of 38°С or higher within 7 days prior to the administration of the first dose of the test or reference drug.
- •Hereditary complement deficiencies.
- •Patients planning to undergo or with a history of bone marrow transplantation.
- •Initial treatment cycle (induction phase) of Soliris®; completed treatment with Soliris® less than 70 days before study inclusion, not related to the current study participation.
- •Vaccination with any live vaccine within 1 month prior to the administration of the first dose of the test or reference drug;
- •Concomitant diseases and conditions which may, in the Investigator's opinion, compromise the patient's safety in case of participation in the study or which could affect the safety data analysis in case of an exacerbation of this disease/condition during the study, including the following:
- •Myocardial infarction or stroke within the last 3 months, severe arrhythmia, NYHA functional class III/IV heart failure;
- •Psychiatric disorders;
- •Immune and endocrine disorders which are not controlled with medications (including decompensated diabetes mellitus and thyroid disorders);
- •Hematologic disorders requiring chemotherapy;
- •Current or prior oncologic disorders, except for successfully treated basal cell carcinoma;
- •Decompensated liver diseases.
- •Acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection confirmed by test results.
- •Active viral hepatitis B and/or C at screening with alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels 5 times the upper limit of normal or higher.
- •Positive syphilis test results.
- •Body mass index (BMI) ≤17 kg/m2 or ≥30 kg/m
- •Pregnancy or breastfeeding.
- •History of tuberculosis, alcohol addiction, medication abuse, or drug addiction.
- •Patient's participation in any clinical studies and/or using of not approved medications in the Russian federation within 30 days before screening.
结局指标
主要结局
Area under the LDH concentration-time curve (LDH AUC) during the maintenance therapy with the test drug or the reference drug
时间窗: week 22
次要结局
- Number/proportion of the patients with stable hemoglobin level during the maintenance therapy with the test drug or the reference drug(week 22)
- Hemoglobin level change during the maintenance therapy with the test drug or the reference drug(week 22)
- Number of donor red blood cell transfusions during treatment with the test product or the reference product.(week 26)
- Number/proportion of patients with breakthrough hemolysis(week 26)
- Area under the LDH concentration-time curve (LDH AUC) during 26-week therapy with the test product or the reference product(week 26)
- Number/proportion of patients with various thrombotic complications developing during treatment with the test product or the reference product.(week 26)
- Number/proportion of patients who needed donor red blood cell transfusions during treatment with the test product or the reference product.(week 26)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use DisorderOpioid-use DisorderNCT04948307Orexo AB437
Unknown
2 期
Efficacy and Safety Study of Budesonide Novolizer Dry Powder Inhaler 200μg to Treat Chinese Patients With Mild to Moderate AsthmaAsthmaNCT01269437NovaMed Pharmaceuticals Inc.332
Unknown
不适用
Comparison of Safety and Efficacy of Needle-Free Injector and Insulin Pen in Patients With T2DMT2DM (Type 2 Diabetes Mellitus)Needle-free InjectorTime in RangeNCT04682795Second Affiliated Hospital, School of Medicine, Zhejiang University200
已完成
3 期
Safety and Tolerability of Glatiramer AcetateRelapsing-Remitting Multiple SclerosisNCT01874145Teva Branded Pharmaceutical Products R&D, Inc.209
进行中（未招募）
2 期
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma MultiformeGlioblastoma Multiforme, AdultNCT04762069CNS Pharmaceuticals, Inc.252